Aligos Therapeutics (NASDAQ:ALGS) and Novavax (NASDAQ:NVAX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, institutional ownership, earnings, risk and valuation.
Valuation and Earnings
This table compares Aligos Therapeutics and Novavax’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Aligos Therapeutics||N/A||N/A||-$108.54 million||($10.87)||-1.46|
|Novavax||$475.60 million||40.30||-$418.26 million||($7.27)||-35.39|
This table compares Aligos Therapeutics and Novavax’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current ratings for Aligos Therapeutics and Novavax, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Aligos Therapeutics currently has a consensus target price of $33.40, indicating a potential upside of 110.86%. Novavax has a consensus target price of $249.60, indicating a potential downside of 2.99%. Given Aligos Therapeutics’ stronger consensus rating and higher possible upside, equities analysts clearly believe Aligos Therapeutics is more favorable than Novavax.
Institutional & Insider Ownership
63.4% of Aligos Therapeutics shares are held by institutional investors. Comparatively, 52.5% of Novavax shares are held by institutional investors. 15.1% of Aligos Therapeutics shares are held by company insiders. Comparatively, 2.1% of Novavax shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Aligos Therapeutics beats Novavax on 9 of the 11 factors compared between the two stocks.
Aligos Therapeutics Company Profile
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a synthetic oligonucleotide that is in Phase I clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company is also developing ALG-020572, an antisense oligonucleotide to decrease HBsAg levels; and ALG-055009, a small molecule THR-Ã agonist for the treatment of non-alcoholic steatohepatitis. In addition, it is developing siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. The company has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting SARS-CoV-2; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Novavax Company Profile
Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.
Receive News & Ratings for Aligos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aligos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.